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BACKGROUND: Breast cancers that are negative for the estrogen receptor (ER), the progesterone receptor (PR), and the HER2
(human epidermal growth factor receptor 2) marker are more prevalent among African women, and the biologically aggressive nature
of these triple-negative breast cancers (TNBCs) may be attributed to their mammary stem cell features. Little is known about expres-
sion of the mammary stem cell marker aldehyde dehydrogenase 1 (ALDH1) in African women. Novel data are reported regarding
ALDH1 expression in benign and cancerous breast tissue of Ghanaian women. METHODS: Formalin-fixed, paraffin-embedded speci-
mens were transported from the Komfo Anoyke Teaching Hospital in Kumasi, Ghana to the University of Michigan for centralized his-
topathology study. Expression of ER, PR, HER2, and ALDH1 was assessed by immunohistochemistry. ALDH1 staining was further
characterized by its presence in stromal versus epithelial and/or tumor components of tissue. RESULTS: A total of 173 women con-
tributed to this study: 69 with benign breast conditions, mean age 24 years, and 104 with breast cancer, mean age 49 years. The pro-
portion of benign breast conditions expressing stromal ALDH1 (n ¼ 40, 58%) was significantly higher than those with cancer (n ¼ 44,
42.3%) (P ¼ .043). Among the cancers, TNBC had the highest prevalence of ALDH1 expression, either in stroma or in epithelial cells.
More than 2-fold higher likelihood of ALDH1 expression was observed in TNBC cases compared with other breast cancer subtypes
(odds ratio ¼ 2.38, 95% confidence interval 1.03-5.52, P ¼ .042). CONCLUSIONS: ALDH1 expression was higher in stromal compo-
nents of benign compared with cancerous lesions. Of the ER-, PR-, and HER2-defined subtypes of breast cancer, expression of ALDH1
was highest in TNBC. Cancer 2013;119:488-94. VC 2012 American Cancer Society.
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INTRODUCTION
Premenopausal breast cancer and tumors that are negative for the estrogen receptor (ER), the progesterone receptor (PR),
and HER2/neu (HER2), a condition commonly known as triple-negative breast cancer (TNBC), are substantially more
common among African and African American women compared with women of other racial/ethnic backgrounds,1-3 as
well as among women with BRCA1 mutation-associated breast cancer.4,5 Approximately 80% of TNBCs belong to the
basal breast cancer subtype, which has been identified as being particularly virulent. Shared ancestry between contempo-
rary African and African American women raises the question of whether African heritage is associated with a heritable
marker for this high-risk pattern of disease. Features of cancer progenitor cells, also known as cancer stem cells, may ulti-
mately account for the biological nature of various breast cancer subtypes, and the presence of mammary stem cells in be-
nign breast tissue has even been linked to future breast cancer risk.6,7 Ongoing research seeks to clarify relationships
between hereditary breast cancer, the basal subtype, and the mammary stem cells. It is therefore appropriate and necessary
to study stem cells in association with breast cancer risk in women with African ancestry.
Mammary stem cells, as identified by cells expressing the marker aldehyde dehydrogenase 1 (ALDH1), appear to be
correlated with malignant transformation of breast tissue and progression into the virulent triple-negative phenotype.8
ALDH1 expression is found in a minority of the breast cancer specimens of white American and European women (19%-
30%).9 Little is known about the frequency of this marker in women of African descent, who are known to have an
increased risk for triple-negative breast cancer, but recent studies suggest that breast cancers expressing this marker are
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more common among African women.10 Our study
presents novel data regarding ALDH1 expression in be-
nign as well as malignant breast tissue of African women
from Ghana.
MATERIALS AND METHODS
The conduct of this research was approved by the Institu-
tional Review Board of the University of Michigan (UM),
Ann Arbor, Michigan, and the Committee on Human
Research Publication and Ethics, Kwame Nkrumah Uni-
versity of Science and Technology College of Health Sci-
ences-School of Medical Sciences, Komfo Anoyke
Teaching Hospital (KATH), Kumasi, Ghana.
Formalin-fixed, paraffin-embedded specimens of
breast tissue from women receiving treatment for benign
and malignant diseases at KATH between 2006 and 2010
(> 90% of specimens were retrieved in 2008 and 2009)
were transported to UM for centralized histopathology
review. These specimens were matched to limited clinico-
pathology data retrieved from KATH pathology reports.
The benign versus malignant nature of all specimens was
confirmed at UM by histopathologic evaluation of slides
stained with hematoxylin and eosin. Immunohistochem-
istry (IHC) was then performed at UM for expression of
ER, PR, HER2, and ALDH1. Malignant specimens were
further characterized by nuclear grade.
Briefly, paraffin-embedded tissue blocks were sec-
tioned at 5 lm and placed on charged slides. Slides were
deparaffinized in xylene and rehydrated through graded
alcohols to buffer. Peroxidase blocking was performed.
No slide pretreatments were used for HER2. Pretreatment
in citrate buffer (pH 6.0) for 15 minutes was used for ER
and PR. Ethylene diamine tetraacetic acid pretreatment
for 15 minutes was used for ALDH1. All slides were
stained on the Dako Automated Immunostainer. HER2
(Dako North America) was used at a dilution of 1:100,
ER (clone ID5; Dako North America) at 1:50, ALDH1
(clone 44; BD Biosciences) at 1:500 or 1:1000, and PR
(clone PgR636; Dako North America) at 1:50. Antibodies
were detected with either EnVisionþ Rabbit horseradish
peroxidase (HRP) (HER2), EnVisionþ Mouse HRP
(ER, ALDH1), or LSABþ HRP (PR) all from Dako
North America. HRP staining was visualized with the
DABþ Kit (Dako North America), and slides were coun-
terstained in hematoxylin. IHC was done by the UM
Comprehensive Cancer Center Tissue Core Research His-
tology and IHC Laboratory.
Specimens were scored as being positive for ER and/
or PR if at least 2% nuclear staining was observed. Benign
breast ducts present in the sections of tumor served as
internal positive controls for the hormone receptors. The
expression of HER2 was scored as either 0 (no staining),
1þ (weak staining in < 10% of tumor cells), 2þ (weak
complete membrane staining in > 10%), or 3þ (strong
complete membrane staining in > 10%). For the purpose
of the present study, HER2 status was dichotomized as ei-
ther positive or negative. A specimen scored as 0 or 1þ
was classified as HER2 negative and positive if it received
an IHC score of 3þ. Fluorescent in situ hybridization,
typically used to assess amplification of the HER2 gene in
cases with a score of 2þ, was not needed, because none of
the specimens in this study had a score of 2þ. ALDH1 was
scored as positive if any staining was seen in the cytoplasm
and negative if no staining was detected. ALDH1 staining
was further characterized by its presence in stromal versus
epithelial and/or tumor components of tissue.
Descriptive statistics were used to summarize clinical
and histopathology information. We applied parametric
and nonparametric statistics, as appropriate, to compare
the distribution of variables between women diagnosed
with benign breast conditions and breast cancer. Expres-
sion of ALDH1 in stroma and epithelial cells was corre-
lated and statistically significant (r ¼ .403, P ¼ .001);
consequently, we analyzed expression of ALDH1 strati-
fied by the site of tissue, whether stroma or epithelial, and
by their joint expression. The latter category, joint expres-
sion, therefore was defined as a sample positive for
ALDH1, if the specimen had been scored positive for
ALDH1 expression either in epithelial and/or in stroma
tissue.
The association between clinicopathologic variables
and expression of ALDH1 biomarkers among women
diagnosed with invasive breast cancer was calculated using
univariate logistic regression analysis. Because a small
number of women (n ¼ 6) were diagnosed with well-dif-
ferentiated (grade 1) tumors, the grade categories of ‘‘well-
differentiated’’ and ‘‘moderately differentiated’’ were col-
lapsed into 1 group, yielding 2 categories of histological
grades ‘‘well and moderately’’ and ‘‘poorly’’ differentiated
for statistical analyses. The variable ALDH1 was dicho-
tomized as positive or negative, with positive defined as
weakly to strongly staining. Finally, we categorized breast
cancers into 4 groups on the basis of IHC results for ER,
PR, and HER2 biomarkers: [HER2þ and ERþ and PRþ],
[HER2 and ERþ and/or PRþ/PR], [HER2þ and ER
and/or PRþ/PR], [HER2 and ER and PR]. For the
statistical analysis, we used the category [HER2 and
ERþ and/or PRþ/PR] as the reference group because of
its histological similarities to luminal A subtype, which
has the most favorable outcome. All statistical tests were
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2-sided, and analyses were performed using SAS version
9.2 (SAS Institute, Cary, NC)
RESULTS
A total of 173 women, of whom 69 were diagnosed with be-
nign conditions of the breast and 104 with breast cancer,
contributed to this study. At the initial clinical presentation,
the mean age of women with benign conditions of the breast
was 24 ( 8.4) years and for women with breast cancer was
49 ( 13.4) years (P < .001). The proportion of women
diagnosed with benign breast conditions and having stromal
ALDH1 expression (n ¼ 40, 58%) was statistically signifi-
cantly higher than the stromal ALDH1 expression among
women with cancer (n ¼ 44, 42.3%; P ¼ .043). We did
not detect statistically significant differences in the propor-
tions of cases staining positive in the epithelial cells express-
ing ALDH1 or in the category of joint expression (Table 1).
ALDH1 expression was similarly low in the epithelial cell–
positive proportions of benign and malignant specimens
(15.9% and 17.3% of cases, respectively).
Of the 104 women with breast cancer, 5 were diag-
nosed with ductal carcinoma in situ and 99 with invasive
carcinoma (Table 2). Among women with invasive carci-
noma, 52 (52.5%) were diagnosed with poorly differenti-
ated, 41 (41.4%) with moderately differentiated, and 6
(6.1%) with well-differentiated histologic grades. A total
of 78 (75.7%) women were diagnosed with ER-negative
breast cancers and 83 (80.6%) with HER2-negative bio-
marker. A total of 58 (56.3%) women were diagnosed
with the triple-negative subtype (HER2 and ER and
PR). Among the 4 subtypes of breast cancer, we observed
the highest prevalence of ALDH1 expression, either in
stroma or in epithelial cells, in the triple-negative subtype.
However, the observed distributions did not reach the
level of statistical significance, presumably due to the
small numbers within each subtype (Table 3).
Results from our univariate logistic regression analy-
sis yielded a 3-fold higher likelihood (odds ratio ¼ 2.99,
95% confidence interval ¼ 0.94-9.46, P ¼ .06) for
expression of ALDH1 in the triple-negative subtype. In
our second analysis, we opted to keep the non–triple-neg-
ative subtypes as the referent and evaluate the probability
of ALDH1 expression in the triple-negative subtype. The
likelihood of ALDH1 expression in the triple-negative
subtypes was more than 2-fold (odds ratio ¼ 2.38, 95%
confidence interval ¼ 1.03-5.52, P ¼ .042) relative to
non–triple-negative subtypes (Table 4). Comparison
results were unchanged when the cases of ductal carci-
noma in situ were excluded from analysis.
DISCUSSION
Differences in breast cancer incidence and outcome
between African American and white American women
are well-documented by population-based data from the
Surveillance, Epidemiology, and End Results Program.
African American women have a lower lifetime risk of
being diagnosed with breast cancer, accounting for
approximately 8% of all estimated new cases in the United
Table 1. Aldehyde Dehydrogenase 1 (ALDH1) Expression in








Mean age, y 24 (8.4) 49 (13.4) <.001
Stromal ALDH1 .043
Negative 29 (42.0) 60 (58.0)
Positive 40 (58.0) 44 (42.3)
Epithelial ALDH1 .813
Negative 58 (84.1) 86 (82.7)
Positive 11 (15.9) 18 (17.3)
Joint expression .099
Negative 29 (42.0) 57 (54.8)
Positive 40 (58.0) 47 (45.2)
Table 2. Distribution of Clinicopathologic Characteristics of
Women Diagnosed With Breast Cancer
Variable N (%)















HER22 and ER2 and PR2 58 (56.3)
HER21 and ER2 and/or PR1/PR2 18 (17.5)
HER22 and ER1 and/or PR1/PR2 19 (18.4)
HER21 and ER1 and PR1 8 (7.8)
Abbreviations: ER, estrogen receptor; HER2 human epidermal growth fac-
tor receptor 2/glioblastoma; PR, progesterone receptor.
a One patient missing estrogen receptor expression staining.
b One patient missing progesterone receptor expression staining.
c One patient missing HER2 staining.
d Five patients missing tumor grade assessment.
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States; however, they account for approximately 13% of
all breast cancer–related deaths.11,12 African American
women are also well known to have higher frequencies of
ER-negative, triple-negative, and early-onset breast can-
cer.1,13-15 The increased prevalence of these patterns
among women with known hereditary susceptibility for
breast cancer through germline BRCA1 mutations then
raises the question of whether African ancestry might also
be associated with inherited predisposition for these high-
risk breast cancer patterns.15
Substantial genetic admixture has occurred
between various race/ethnicity-defined subsets of the
American population, resulting in a significant degree of
ancestral heterogeneity within many African American
families. Nonetheless, a disproportionate risk for breast
cancer mortality has been consistently demonstrated for
women who identify themselves as African American.
Poverty and inadequate health care access are also more
prevalent among African Americans, and it is therefore
challenging to disentangle the effects of socioeconomic
disadvantage from those of inherited susceptibility on
breast cancer risk. To learn more about breast cancer pre-
disposition that might be related to inherited factors
associated with African heritage, it is appropriate to
study available data on the breast cancer burden of Afri-
can populations that share ancestry with African Ameri-
cans. Most of the colonial slave trade from the 1500s to
the 1800s occurred between ports along the Atlantic
coast and western, sub-Saharan Africa, including the
country of Ghana.16,17
Existing studies of breast cancer in European/
white American women, African American women,
and women from sub-Saharan Africa reveal provoca-
tive patterns. Frequencies of early-onset, ER-negative,
and triple-negative breast cancer are lowest for
women with European heritage, highest for African
women, and intermediate for African American
women.1,2,19 These patterns suggest that extent of
African ancestry could be associated with an inherited
susceptibility for aggressive patterns of breast cancer
diagnosed at younger ages.
Table 3. Prevalence of Aldehyde Dehydrogenase 1 (ALDH1)









HER22 and ER2 and PR2 30 (51.7) 28 (48.3)
HER21 and ER2 and/or PR1/PR2 13 (72.2) 5 (27.8)
HER22 and ER1 and/or PR1/PR2 13 (68.4) 6 (31.6)
HER21 and ER1 and PR1 4 (50.0) 4 (50.0)
Epithelial
HER22 and ER2 and PR2 27 (46.6) 31 (53.4)
HER21 and ER2 and/or PR1/PR2 13 (72.2) 5 (27.8)
HER22 and ER1 and/or PR1/PR2 13 (68.4) 6 (31.6)
HER21 and ER1 and PR1 4 (50.0) 4 (50.0)
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth fac-
tor receptor 2/glioblastoma; PR, progesterone receptor.
Table 4. Likelihood of Aldehyde Dehydrogenase 1 (ALDH1) Expression by Clinicopathologic
Characteristics
Clinicopathologic Feature ALDH1-Positive OR (95% CI) P
Age group
Age < 50 y vs age  50 y 23/46 vs 17/38 1.23 (.52-2.92) .624
Estrogen receptor
Negative vs positive 36/76 vs 10/27 1.54 (.62-3.85) .355
Progesterone receptor
Negative vs positive 36/78 vs 10/25 1.28 (.51-3.22) .591
Grade
3 vs 1 and 2 27/52 vs 18/47 1.84 (.82-4.14) .139
HER2 biomarker
Negative vs positive 38/83 vs 8/20 1.05 (.36-3.12) .920
Subtype
[HER2þ and ERþ and PRþ] vs 4/8 vs 6/19 2.60(.39-17.4) .324
[HER2 and ERþ and/or PRþ/PR]
[HER2þ and ER and/or PRþ/PR] vs 5/18 vs 6/19 1.18 (.27-5.18) .825
[HER2 and ERþ and/or PRþ/PR]
[HER2 and ER and PR] vs 31/58 vs 6/19 2.99 (.94-9.46) .063
[HER2 and ERþ and/or PRþ/PR]
TNBC vs none-TNBCa 31/58 vs 15/45 2.38 (1.03-5.52) .042
Abbreviations: CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2/glioblas-
toma; OR, odds ratio; PR, progesterone receptor.
a TNBC, triple-negative breast cancer (HER2 and ER and PR); None-TNBC, all other subtypes combined.
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The concept of cancers arising from stem cells was
introduced more than a century ago,19 and has been
applied to research in the study of hematologic malignan-
cies, multiple myeloma, and melanoma as well as brain,
prostate, colon, pancreatic, and head and neck cancers.20-27
Hematopoietic stem cells are multipotent cells that are
normally found in the bone marrow and are responsible
for producing all of the adult hematopoietic lineages.
These cells have the ability to self-renew and undergo
differentiation into phenotypically diverse populations of
tumor cells. It is theorized that cancer stem cells drive the
growth and spread of malignant tumors. It stands to rea-
son that cancer stem cells have a phenotype defined by the
cell of origin and by an oncogenic transformation event.
In an attempt to find shared cancer stem cell markers,
recent studies have focused on conserved stem and pro-
genitor cell functions. These functional markers may be
inherited by the malignant stem cell compartment across
multiple histological subtypes of cancer from the same
tissue of origin.6,9,10,28-30
Table 5. Selected Studies of Aldehyde Dehydrogenase 1 (ALDH1) Expression in Breast Tissue





Kunju et al8 (2011) 5% epithelial cells with
cytoplasmic staining.
Case-control study of benign breast
biopsies in women who subsequently
developed breast cancer versus those
who did not develop breast cancer.
Epithelial and stromal ALDH1 expression
associated with increased risk of future
breast cancer.
Expanded stromal staining




Scoring based on foci with
maximal staining.
13% of controls.
Ginestier et al9 (2007) Any cytoplasmic staining
(ALDH1-positive
cases noted to have only
5% cells
expressing stain).
19% University of Michigan cases. ALDH1-positivity associated with high-grade,
estrogen receptor–negative tumors and
poor prognosis.
30% Institut Paoli-Calmettes cases.
Nalwoga et al10 (2010) Combination of ALDH1 staining
intensity and proportion of
cells staining positive.
48% of Ugandan breast cancer
cases.
ALDH1 expression associated with
high-grade tumors and estrogen
receptor–negativity
Zhou et al32 (2010) N/A N/A Meta-analysis of cancer stem cell studies in
breast cancer; studies using ALDH1 as a
cancer stem cell marker demonstrated
strongest association between cancer
stem cells and poor prognosis.
Neumeister et al33 (2010) N/A N/A Multiplexed staining for ALDH1 coexpressed
with CD44 as a marker of cancer stem
cells was associated with poor prognosis.
Park et al34 (2010) 10% ALDH1 staining 9% pure IDC ALDH1 positivity correlated with basal-like
and HER2/neu-overexpressing tumors.6% IDC plus DCIS




Combination of ALDH1 staining
intensity and proportion of
cells staining
positive
31% of inflammatory breast cancer
cases
ALDH1-positivity associated with poor
prognosis among cases of inflammatory
breast cancer.
Yoshioka et al36 (2011) Any cytoplasmic staining in
cancer cells
26% IDC ALDH1 expression associated with poor
prognosis in node-positive breast cancer.14% DCIS
Resetkova et al37 (2010) Combination of ALDH1 staining
intensity and proportion of
cells staining
positive.
18% all cancers Tumor ALDH1 expression correlated with
basal-like tumors.
39% basal tumors Stromal ALDH1 expression correlated with
improved outcome.
Heerma van Voss et al38
(2011)
Combination of ALDH1 staining




cancers and 41.5% sporadic
cancers with tumoral expression.
BRCA1 mutation-associated cancers more
likely to be ALDH1-positive.
58.5% BRCA1 mutation-associated
cancers and 43.9% sporadic
cancers with stromal expression.
Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; N/A, not applicable.
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ALDH1 is an intracellular enzyme that is responsi-
ble for the oxidation of aldehydes to carboxylic acids.31
Ginestier and colleagues showed that stem cell–like popu-
lations in breast tissue are characterized by the expression
of ALDH1, and breast cancer stem cells have been isolated
on the basis of increased ALDH1 expression.5,8 This
group further demonstrated that in the breast, ALDH1
expression is considered to be a marker of both normal
and malignant stem and progenitor cells. ALDH1 positiv-
ity has been associated with features of aggressive tumors,
such as high histological grade, high mitotic count, p53
expression and ER/PR negativity. In addition, ALDH1
expression has been associated with poor clinical out-
come.7-9,33-39 Finally, ALDH1 expression within benign
breast biopsies has been associated with future breast can-
cer risk.8 These studies are summarized in Table 5.
ALDH1 can be detected by standard IHC staining
techniques as a cytoplasmic protein. Consistent with the
theory that stem cells comprise a minority of tumor tissue,
specimens that are positive for ALDH1 frequently have
fewer than 10% of cells expressing this marker. At this
time, there is no consensus regarding optimal scoring and
threshold levels for ALDH1 positivity, but published
studies thus far generally reveal fewer than one-third of
breast cancers to be positive for this marker. Two notable
exceptions, however, are breast cancer cases related to
BRCA1 mutations38 and breast cancers from African
women,10 where ALDH1 positivity has been reported in
78% and 48% of cases, respectively.
Substandard and/or poor, delayed tissue fixation
can result in diminished antigenicity and lower molecular
marker expression on subsequent IHC evaluation.
Although all IHC studies for this project were performed
at UM, specimens were initially processed and formalin-
fixed in Ghana. Although the understaffed surgery and
pathology programs in developing countries such as
Ghana can potentially yield decreased antigenicity
because of suboptimal tissue fixation, it would be expected
that a variety of markers would be affected in a compara-
bly suppressed fashion. The observation of decreased ER,
PR, and HER2 expression in contrast to relatively
increased expression of ALDH1 suggests that our findings
are not explained by generalized decreased antigenicity.
In summary, the cancer stem cell hypothesis has fun-
damental implications for cancer biology in addition to
clinical implications for cancer risk assessment, early detec-
tion, prognostication, and prevention. Our study lends
support to the stem cell hypothesis by demonstrating
increased expression of ALDH1 in breast specimens from
the western sub-Saharan country of Ghana, a population
known to be characterized by higher prevalence of the
TNBC pattern. Specifically, there appears to be signifi-
cantly increased expression of this mammary stem cell
marker in the stromal components of benign Ghanaian
breast specimens, and expression of ALDH1 within Gha-
naian cancers was highest for triple-negative tumors. These
data, together with well-documented evidence of the high
prevalence of TNBC among women with African ancestry
in the United States as well as in women in continental
Africa, suggests that stem cell marker expression in benign
tissue may well be associated with future risk of these bio-
logically aggressive tumors. Furthermore, some prelimi-
nary case-control data already suggest an association
between ALDH1 expression in benign breast tissue and
breast cancer risk. Compared to existing data on ALDH1
expression in the breast cancers of white American and
European women, we found that mammary stem cells (as
detected by ALDH1 expression) represent an expanded
population of the breast tissue of women from Ghana.
These results have provocative implications regard-
ing the possibility that breast cancer disparities between
African American and white American women may have
an inherited, genetic explanation. Although studies of
mammary stem cell expression in African populations add
compelling observations to the discussion of breast cancer
disparities between race/ethnicity-identified populations,
it is critical that future studies specifically seek to define
expression of this marker in African American women.
These data are presently unavailable but will be relevant to
discussions of breast cancer disparities within the United
States. Further studies are necessary to confirm our find-
ings, and to fully understand their clinical significance
regarding the biology of breast cancer in international
populations. This work also demonstrates the value of
global breast oncology collaborative efforts.
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